Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases
Abstract The development of brain metastases (BMs) in breast cancer (BC) patients remains a challenging complication. Current clinical practice guidelines recommend local treatment of BMs without changing systemic therapy (CST) in patients with stable extracranial disease. We retrospectively investi...
Guardado en:
Autores principales: | Omar Alhalabi, Zaid Soomro, Ryan Sun, Elshad Hasanov, Aya Albittar, Debu Tripathy, Vicente Valero, Nuhad K. Ibrahim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b13d01d1e9f04a52984ccf0fe8205030 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Zosteriform Cutaneous Distant Metastases as Onset of Relapsing Melanoma
por: Daniel Morgado-Carasco, et al.
Publicado: (2019) -
Emerging role of brain metastases in the prognosis of breast cancer patients
por: Hambrecht A, et al.
Publicado: (2011) -
Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
por: Peng Yuan, et al.
Publicado: (2017) -
Genomic and Transcriptomic Profiling of Brain Metastases
por: Christopher P. Wardell, et al.
Publicado: (2021) -
MiRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer
por: Byunghee Yoo, et al.
Publicado: (2021)